Promoting transparency in pharmaceutical industry-sponsored research

American Journal of Public Health

Volumn 102, Issue 1, 2012, Pages 72-80

  Ross, Joseph S ^a   Gross, Cary P ^a   Krumholz, Harlan M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ETHICS; FINANCIAL MANAGEMENT; HUMAN; INFORMATION DISSEMINATION; INTERPERSONAL COMMUNICATION; MEDICAL RESEARCH; PUBLICATION; PUBLISHING; REGISTER; STANDARD;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DISCLOSURE; DRUG INDUSTRY; HUMANS; INFORMATION DISSEMINATION; PUBLICATION BIAS; PUBLICATIONS; REGISTRIES; RESEARCH SUPPORT AS TOPIC;

EID: 84857342101     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300187     Document Type: Article

References (77)

1. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454-465. (Pubitemid 36119966)
2. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170(4):477-480. (Pubitemid 38293642)
3. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-forprofit organizations: 2000-2005. JAMA. 2006;295(19):2270-2274. (Pubitemid 43736577)
4. Davidoff F. Between the lines: navigating the uncharted territory of industry- sponsored research. Health Aff (Millwood). 2002;21(2):235-242.
5. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. JAMA. 2001;286(10): 1232-1234. (Pubitemid 33015555)
6. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academy Press; 2009.
7. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House; 2004.
8. Kassirer JP. On the Take: How America's Complicity With Big Business Can Endanger Your Health. New York: Oxford University Press; 2004.
9. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(7):921-928. (Pubitemid 37430464)
10. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry- sponsored research. Lancet. 2000; 356(9230):635-638. (Pubitemid 30627590)
11. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 2002;325(7358):249.
12. Rennie D. Fair conduct and fair reporting of clinical trials. JAMA. 1999; 282(18):1766-1768. (Pubitemid 29533609)
13. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008;66(9):1909-1914. (Pubitemid 351454041)
14. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282(18): 1752-1759. (Pubitemid 29533606)
15. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? JAMA. 2006;295(14):1704-1706.
16. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002;190(9):583-592.
17. Spielmans GI, Biehn TL, Sawrey DL. A case study of salami slicing: pooled analyses of duloxetine for depression. Psychother Psychosom. 2010;79(2): 97-106.
18. Gøtzsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol. 1989;36(5):429-432. (Pubitemid 19135202)
19. Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet. 1996;347(9007): 1024-1026. (Pubitemid 26112179)
20. Greenland P, Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA. 2008;299(8):953-955. (Pubitemid 351397071)
21. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars-drug promotion in a competitive marketplace. N Engl J Med. 1994; 331(20):1350-1353. (Pubitemid 24347007)
22. Stephens MD. Marketing aspects of company-sponsored postmarketing surveillance studies. Drug Saf. 1993; 8(1):1-8. (Pubitemid 23056750)
23. Psaty BM, Rennie D. Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry. JAMA. 2006;295(23):2787-2790.
24. Krumholz SD, Egilman DS, Ross JS. Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. Arch Intern Med. 2011;171(12):1100-1107.
25. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008;149(4):251-258.
26. Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139(7):539-546.
27. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145(4):284-293. (Pubitemid 46768613)
28. Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry. 2003;183:22-27. (Pubitemid 36831259)
29. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med. 2007; 4(9):e286.
30. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. Soc Stud Sci. 2009;39(2):171-198.
31. Sismondo S, Nicholson SH. Publication planning 101. J Pharm Pharm Sci. 2009;12(3):273-279.
32. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299(15):1800-1812. (Pubitemid 351549971)
33. Golden GA, Parochka JN, Overstreet KM. Medical education and communication companies: an updated in-depth profile. J Contin Educ Health Prof. 2002; 22(1):55-62.
34. Ross JS, Lurie P, Wolfe S. Medical Education Service Suppliers (MESS): A Threat to Physician Education. Available at: http://www.citizen.org/ publications/publicationredirect.cfm?ID=7142. Accessed January 17, 2011. HRG publication no. 1530.
35. Rennie D, Flanagin A. Authorship! Authorship! Guests, ghosts, grafters, and the two-sided coin. JAMA. 1994;271(6): 469-471.
36. Rennie D, Yank V, Emanuel L. When authorship fails. A proposal to make contributors accountable. JAMA. 1997;278(7):579-585. (Pubitemid 27353608)
37. PLoS Medicine Editors. Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med. 2009;6(9):e1000156.
38. SmithKline Beecham Pharmaceuticals. Re: Paxil, Case Study Publications for Peer Review. Available at: http://i.bnet.com/blogs/par000570546-59- casppercase-study-pub-for-peer-review.pdf?tag=content;selector-perfector Accessed January 17, 2011.
39. Fugh-Berman A. The corporate coauthor. J Gen Intern Med. 2005;20(6): 546-548. (Pubitemid 41003812)
40. Mello MM, Clarridge BR, Studdert DM. Academic medical centers' standards for clinical-trial agreements with industry. NEngl JMed. 2005;352(21):2202-2210. (Pubitemid 40727087)
41. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004; 291(20):2457-2465. (Pubitemid 38669189)
42. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004;171(7):735-740. (Pubitemid 39319090)
43. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.
44. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267(3):374-378.
45. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746): 867-872.
46. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279(4):281-286.
47. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003; 290(4):495-501. (Pubitemid 37430503)
48. Misakian AL, Bero LA. Publication bias and research on passive smoking: comparison of published and unpublished studies. JAMA. 1998;280(3):250-253. (Pubitemid 28493898)
49. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315(7109):640-645. (Pubitemid 27387174)
50. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE. 2008; 3(8):e3081.
51. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials. Gov: a cross-sectional analysis. PLoS Med. 2009;6(9):e1000144.
52. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008;5(11):e217.
53. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431- 1443. (Pubitemid 351482735)
54. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358(17):1819-1828. (Pubitemid 351581194)
55. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007;297(3):308-311. (Pubitemid 46143310)
56. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40(7): 762-772. (Pubitemid 32595260)
57. Jureidini JN, McHenry LB, Mansfield PB. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Saf Med. 2008;20(1):73-81. (Pubitemid 351526054)
58. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry- sponsored trials of gabapentin for offlabel use. N Engl J Med. 2009;361(20): 1963-1971.
59. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1): 66-71. (Pubitemid 38082872)
60. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204-1215. (Pubitemid 40720980)
61. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008; 299(15):1813-1817. (Pubitemid 351549972)
62. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med. 2000; 343(21):1520-1528.
63. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ. 2007;334(7585):120-123. (Pubitemid 46173951)
64. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al. "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, " N Engl J Med 2000;343:1520-8 [Editorial]. N Engl J Med. 2005;353(26):2813- 2814.
65. Drazen JM, Van Der Weyden MB, Sahni P, et al. Uniform format for disclosure of competing interests in ICMJE journals. CMAJ. 2009;181(9):565.
66. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007; 297(11):1216-1223. (Pubitemid 46469916)
67. Cain DM, Loewenstei G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Stud. 2005;34(1):1-25. (Pubitemid 40549835)
68. Hrynaszkiewicz I, NortonML, Vickers AJ, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ. 2010;340:C181.
69. Hrynaszkiewicz I, Altman DG. Towards agreement on best practice for publishing raw clinical trial data. Trials. 2009;10:17.
70. Vickers AJ. Whose data set is it anyway? Sharing raw data from randomized trials. Trials. 2006;7:15.
71. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.
72. National Institutes of Health. NIH Grants Policy Statement, Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General, Section 8: Administrative Requirements, 8.2.3.1 Data Sharing Policy; October 15, 2010. Available at: http://grants.nih.gov/grants/policy/nihgps-2010/nihgps-ch8.htm#- Toc271264950. Accessed January 17, 2011.
73. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med. 2009;169(21):1976-1985.
74. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104(19):2280-2288. (Pubitemid 33049509)
75. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89(2): 204-209. (Pubitemid 34132911)
76. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146(4):591-604. (Pubitemid 37281702)
77. Godlee F, Clarke M. Why don't we have all the evidence on oseltamivir? BMJ. 2009;339:b5351.